Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Slides:



Advertisements
Similar presentations
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Advertisements

Mild Cognitive Impairment
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁 董冠廷 詹鎮遠 陳柏廷.
Cognitive Development Dementia. Stages: Preclinical First sign: memory loss for the familiar First sign: memory loss for the familiar Biological changes.
Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Volume 3, Issue 4, Pages (November 2017)
Embracing Their Reality: Making Assisted Living Dementia-Friendly
Nat. Rev. Neurol. doi:10/1038/nrneurol
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Nat. Rev. Neurol. doi: /nrneurol
Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample  Marie Eckerström,
by Edward J. Goetzl, Adam Boxer, Janice B. Schwartz, Erin L
Imaging AD Progression Amyloid Imaging Agents.
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Life expectancy at birth in all countries included
Cognitive Disorders and Aging
Figure 2 The US Centers for Disease Control and
Figure 4 Time course of the development of physiological changes
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
New Therapies in Alzheimer's Disease
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Cerebrospinal fluid levels of neurofilament light chain
Figure 2 Overview of risk factors for Parkinson disease dementia
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Patterns of brain atrophy in Alzheimer disease
Nat. Rev. Neurol. doi: /nrneurol
Early Dementia Distinguishing AD From MCI
Figure 2 Proposed mechanism of Guillain–Barré
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 The new concept of prodromal RBD
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
New FDA Guidance on Early Alzheimer’s Disease
Figure 3 Proportion of patients for whom NEDA
Figure 1 Diagnostic tiers of Parkinson disease as single disease
Probing the Biology of Alzheimer's Disease in Mice
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W
Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Genetic pleiotropy in ALS
Figure 1 Evolution of multiple sclerosis
Figure 1 The trajectory of cognitive ageing
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Anatomical patterns of neuropathy
Figure 3 Stroke-related deaths and DALYs by country development status
Nat. Rev. Neurol. doi: /nrneurol
Todd E. Golde, Lon S. Schneider, Edward H. Koo  Neuron 
Figure 6 Combining population-wide and high-risk strategies
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Frequency of vertigo and dizziness syndromes
Figure 1 Tau PET images in patients with Alzheimer disease
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
Nat. Rev. Neurol. doi: /nrneurol
Baseline Characteristics of the Subjects
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Rett syndrome severity and age at diagnosis by mutation type
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 A case of early-onset PSD
Massimo S. Fiandaca, Mark E. Mapstone, Amrita K. Cheema, Howard J
GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS  Betty M. Tijms, Mara ten Kate, Sander C.J.
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;
Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;
Presentation transcript:

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD) Figure 1 | Hypothetical staging model of sporadic Alzheimer disease (AD). Although many individuals with mild cognitive impairment (MCI) progress to dementia, some remain stable or revert to normal cognitive function. The proposed staging is based on the progression of the disease and comprises two bits of information: AD stage as identified at diagnosis, and the current stage. The main categories in this system include the preclinical (or presymptomatic) phase (1), the prodromal stage, also known as MCI (2), and the dementia syndrome (3). Hampel, H. & Lista, S. (2015) The rising global tide of cognitive impairment Nat. Rev. Neurol. doi:10.1038/nrneurol.2015.250